Omid Hamid
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers 216
- CAR-T cell therapy research 176
- Cutaneous Melanoma Detection and Management 49
- Colorectal Cancer Treatments and Studies 29
- Immunology top 0.05%
- Immunotherapy and Immune Responses 105
- Biological Psychiatry top 0.5%
- Pulmonary and Respiratory Medicine top 0.2%
- Cancer Research top 0.5%
-
- Melanoma and MAPK Pathways 114
-
- Monoclonal and Polyclonal Antibodies Research 35
-
- Cancer Research and Treatments 29
- Co-authors
- F. Stephen HodiJeffrey S. WeberJedd D. WolchokSteven O’DayCaroline RobertCélèste LebbéDavid M. BermanAdil Daud
- Journals
- Journal of Clinical Oncology (186 papers)Annals of Oncology (49 papers)Clinical Cancer Research (18 papers)
- Partner nations
- United StatesFranceAustralia
In The Last Decade
Omid Hamid
396 papers receiving 25.9k citations
Hit Papers
Peers
Comparison fields: 5 of 135
- Oncology 21.3k
- Immunology 9.8k
- Biological Psychiatry 548
- Pulmonary and Respiratory Medicine 4.9k
- Cancer Research 1.9k
Countries citing papers authored by Omid Hamid
This map shows the geographic impact of Omid Hamid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omid Hamid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omid Hamid more than expected).
Fields of papers citing papers by Omid Hamid
This network shows the impact of papers produced by Omid Hamid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omid Hamid. The network helps show where Omid Hamid may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Omid Hamid, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 1 | |
| 5 | 2023 | 7 | |
| 6 | 2023 | 0 | |
| 7 | 2023 | 1 | |
| 8 | 2020 | 52 | |
| 9 | 2020 | 165 | |
| 10 | 2019 | 58 | |
| 11 | 2019 | 30 | |
| 12 | 2018 | 42 | |
| 13 | 2017 | 336 | |
| 14 | Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanomabreakdown → | 2016 | 435 |
| 15 | Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibodybreakdown → | 2016 | 281 |
| 16 | 2015 | 97 | |
| 17 | 2014 | 51 | |
| 18 | 2014 | 34 | |
| 19 | 2013 | 338 | |
| 20 | 2009 | 460 |
About Omid Hamid
Omid Hamid is a scholar working on Oncology, Immunology and Biological Psychiatry, having authored 414 papers that have together received 26.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (216 papers), CAR-T cell therapy research (176 papers), Melanoma and MAPK Pathways (114 papers), Immunotherapy and Immune Responses (105 papers), Cutaneous Melanoma Detection and Management (49 papers), Monoclonal and Polyclonal Antibodies Research (35 papers), Cancer Research and Treatments (29 papers) and Colorectal Cancer Treatments and Studies (29 papers). The work is most often cited by research in Oncology (21.3k citations), Immunology (9.8k citations) and Biological Psychiatry (548 citations). Omid Hamid has collaborated with scholars based in United States, France and Australia. Frequent co-authors include F. Stephen Hodi, Jeffrey S. Weber, Jedd D. Wolchok, Steven O’Day, Caroline Robert, Célèste Lebbé, David M. Berman, Adil Daud, Michele Maio and Antoni Ribas. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, Cancer Research and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.